BioSpace News Archive

Synedgen announced that research elucidating the role of complex sugars and ions and their potential role in the treatment of diseases was published in the journal, Macromolecular Theory and Simulation.

The primary objectives of the STITCH study are to assess the success of horizontal meniscus tear repair using Ceterix’s NovoStitch meniscal repair system or other suture-only techniques, and to assess improvements in knee pain and function after repair.

Purdue Pharma, L.P. today announced the funding of three grants for investigator-initiated research on developing clinically relevant and useful tools to assist in the assessment of chronic pain, including research on Virtual Reality (VR) technology to assess chronic pain intensity; electroencephalograph (EEG) alpha activity as an objective measurement of pain; and the relationship between pain and attentional processes and cognitive functioning.

International medical technology firm EarlySense, which specializes in health monitoring products for the medical and consumer markets, will relocate its U.S. office to West Cummings Park in Woburn from its current location in Waltham.

Dr. Isacson is Professor of Neurology (Neuroscience) at Harvard Medical School and Professor of Neurology at Massachusetts General Hospital. He is the founding Director of the Neuroregeneration Research Institute at McLean Hospital/Harvard Medical School.

Cerus Corporation today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.0 million, before deducting estimated offering expenses payable by Cerus.

MMJ PhytoTech is pleased to advise that it has received results from the first 10 patients who participated in the Phase 2 clinical trial undertaken by MMJ PhytoTech.

Nath succeeds Franz Walt, who served as President from 2014-2017.

The new agreement names TransPerfect as the strategic supplier of language services, including document translation, digital content localization, and interpretation services.

TACT, a prospective, open-label, single-arm pivotal clinical study, has enrolled 110 prostate cancer patients across 13 research sites in the U.S.